Pharmaceutical

EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage

The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.

Jul 28, 2024 - 04:00
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.
Read the original article

Tags:

Previous Article

FDA committee proposes overhaul of perioperative lung cancer trials 

Next Article

FDA approves Sun Pharma’s JAK inhibitor for alopecia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital

STAT+: Dana-Farber CEO on Mass General split: Boston ne...

Oct 10, 2023

Opinion: Adopting the term ‘preaddiction’ would be a serious mistake

Opinion: Adopting the term ‘preaddiction’ would be a se...

May 25, 2023

Listen: Vivek’s star turn, leaky drug data, & biotech as family business

Listen: Vivek’s star turn, leaky drug data, & biotech a...

Aug 25, 2023